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Background: The use of fluorescence differential pathlength spectroscopy (FDPS)
has the potential to provide real-time information on photosensitiser pharmacokinetics,
vascular physiology, and photosensitizer photobleaching based dosimetry of tumors in
the oral cavity receiving m-tetrahydroxyphenylchlorin (mTHPC) photodynamic therapy
(PDT). Reflectance spectra can be used provide quantitative values of oxygen saturation,
blood volume fraction (DVF), blood vessel diameter, and to determine the local optical
properties that can be used to correct raw fluorescence for tissue absorption.
Patients and methods: Twenty-seven lesions in the oral cavity, either dysplasias or
cancer were interrogated using FDPS, before and immediately after the therapeutic
illumination.
Results: The average tumor center (TC) to normal mucosa (NM) ratio of fluorescence
was 1.50± 0.66. mTHPC photobleaching was observed in 24 of the lesions treated. The
average extent of photobleaching was 81 ± 17%. Information from FDPS spectroscopy
coupled with the clinical results of the treatment identified three types of correctable
errors in the application of mTHPC-PDT: Two patients exhibited very low concentrations
of photosensitizer in TC, indicating an ineffective i.v. injection of photosensitiser or
an erroneous systemic distribution of mTHPC. In one in tumor we observed no
photobleaching accompanied by a high DVF in the illuminated tissue, suggesting that
the presence of blood prevented therapeutic light reaching the target tissue. All three of
the these lesions had no clinical response to PDT. In four patients we observed less than
50% photobleaching in the tumor margins, suggesting a possible geographic miss of the
oncological safety margin. One patient in this group had a recurrence within 2 months
after PDT even though the initial response was good.
Conclusion: The integration of FDPS to clinical PDT of head and neck tumors yields
data on tissue physiology, photosensitiser content, and photobleaching that can help
identify treatment errors that can potentially be corrected.
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Introduction
Photodynamic therapy (PDT) is a therapeutic modality that
involves the administration of visible light and a photo-active
drug, or photosensitizer, that results in localized tissue destruc-
tion without systemic toxicity. Upon activation of the photosensi-
tizer is activated; light energy is transferred to molecular oxygen,
which leads to the formation of reactive oxygen species (ROS),
notably singlet oxygen. Subsequently these ROS interact with
critical biomolecules, oxidizing them. This leads to the destruc-
tion of the illuminated tissue through a range of mechanisms that
include apoptosis, necrosis, destruction of tumor vasculature and
an immune response against tumor cells [1–3].
Several articles have been published outlining the clinical
results of meta-tetrahydroxyphenylchlorin (mTHPC) mediated
PDT of the head and neck tumors [4–12]. While many report
early experiences, a number of these publications report clinical
complete responses around 69–95% of carefully selected patients
with early stage oral cavity cancer [5–12]. However, despite the
use of rigorous patient and lesion selection criteria and the
standardize delivery of light, a small but significant number of
tumors show incomplete response or do not respond to ther-
apy. There are numerous factors that can cause these failures.
Treatment related factors, in other words sub-optimal PDT could
play a role that can be improved with better techniques. In this
manuscript we have aimed to attempt to unravel some of these
treatment-related factors.
The local therapeutic effect of PDT is driven by the produc-
tion of ROS and depends on the presence of three components:
light, photosensitizer, and oxygen [1, 13, 14]. Previous investiga-
tions have shown significant inter- and intra-subject variations
in parameters such as photosensitizer concentration and phar-
macodynamics, the optical properties of tissue and concomitant
differences in the effective fluence and fluence rate, and the ability
of the tissue vasculature to supply sufficient oxygen during PDT
[15–18]. Each of these parameters can be different for individ-
ual lesions and patients. They can be interdependent and change
dynamically during therapy [19, 20]. Differences in these interre-
lated parameters can lead to variations in the photodynamic dose
that is delivered to the treatment volume and to the surrounding
normal tissues. These differences may be the source of inadequate
therapeutic response.
Better understanding of these variations and interrelation-
ships can help us analyze treatment failures on individual treat-
ment basis. Optical spectroscopy is a non-invasive method of
monitoring these PDT related variables [13–25]. Reflectance
spectroscopy utilizes the dominant absorption bands of oxy-
and de-oxyhemoglobin in tissue to determine parameters that
characterize the local vascular physiology [13, 14, 21]. Flu-
orescence spectroscopy can be used to determine the pres-
ence of the photosensitiser and may be used to monitor
the photosensitizer concentration and photosensitiser photo-
bleaching during PDT [16–18]. The combination of monitor-
ing reflectance spectroscopy and fluorescence spectroscopy in
the same tissue volume may also provide complimentary infor-
mation on the relationship between photobleaching and the
presence of oxygen during therapy.
Over the past decade our group has developed various optical
spectroscopic techniques including the use of differential path-
length spectroscopy (DPS) [22, 23] and the associated technique
florescence differential path-length spectroscopy (FDPS) [25] for
monitoring PDT. FDPS utilizes two optical fibers one for deliv-
ery of light (white light for DPS and 652 nm excitation light for
FDPS), and both for collecting light reflected (or emitted) from
tissue. The difference between the two collected signals limits
the contribution from long path-length photons. This enables
the optical sampling of a small volume of tissue immediately
beneath the fiber-probe. FDPS can accommodate large variations
in background absorption using a simple correction algorithm.
This makes it particularly valuable for photosensitizer fluores-
cence spectroscopy in-vivo, during PDT, when the background
absorption can change dramatically. Another advantage of FDPS
is that the collection volume can be adjusted to match the rel-
evant dimensions of the application. For fluorescence measure-
ments of photosensitizers, it is critical to selectively interrogate
a relevant tissue volume to avoid averaging photosensitiser con-
centrations over a volume that is either deeper or shallower than
the intended sampling volume. It is noteworthy that while FDPS
remains dependant on the scattering coefficient of tissue, this
is expected to have a relatively small influence on the signals
collected particularly in tissues of the same type [23, 25].
We have applied FDPS to the clinical setting and to healthy
volunteers and reported the initial feasibility data in our previ-
ous publication [25]. The results of this pilot study indicated that
FDPS could be effectively incorporated in a clinical setting and
that FDPS correctly estimated the absence of mTHPC in con-
trol patients and detected mTHPC photobleaching in tissue vol-
umes that received treatment light following PDT. Given these
initial results we have utilized FDPS to analyze optical charac-
teristics of oral cavity tumors being routinely treated with PDT
in our institute. The clinical treatment protocol was kept stan-
dard to allow evaluation of treatment failures. This manuscript
reports the reflectance and fluorescence spectroscopic analysis of
these patients and attempt to explain treatment failures based on
spectroscopic measurements.
Materials and Methods
Patient Population and Clinical Methods
The patients undergoing PDT for the treatment of oral cavity
cancers were included in the project. The study was approved
by the Medical Ethics Review Board of the NKI/AvL Hospital
(PTC 10.1975/N10OPT) and was conducted in accordance with
local guidelines for the treatment of head and neck cancer. Both
superficial and deep-seated tumors were included. These deep-
seated tumors, that were treated using interstitial PDT, were ana-
lyzed separately and will be presented in a separate report. All
of the patients reported in this manuscript had squamous cell
carcinoma (SCC) or carcinoma in situ (CIS) of the oral mucosa,
without regional or distant metastasis and not deeper than 5mm
as measured by ultrasound (T1N0M0 or TisN0M0 by AJCC
staging system). Primary tumors, second primary tumors and
recurrences of earlier treated tumors were included. The pho-
tosensitizer Foscan R© (m-tetrahydroxyphenylchlorin, m-THPC)
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was injected intravenously in a proximal vein in the arm at a dose
of 0.15mg/kg. The surface illumination procedure took place 4
days after the photosensitizer injection. Depending on the loca-
tion of the tumor the procedure was either performed under
general anesthesia or local anesthesia. FDPS measurements were
acquired from three locations at the tumor center (TC), three
locations on adjacent normal appearing mucosa which had been
illuminated in the oncological safetymargin (TM) and three loca-
tions distant from the tumor, in normal mucosa (NM) in the oral
cavity, located under shielding (and therefore receiving no thera-
peutic light) (NM), immediately before and immediately after the
PDT procedure. Therapy was performed with light from diode
laser 652 nm (Biolitec, Germany), using amicrolens diffuser, with
a minimum margin of 5mm around the visible tumor, using a
fluence rate of 100mWcm−2 to a fluence of 20 Jcm−2.
Fluorescence Differential Path-Length
Spectroscopy
The clinical application of fluorescence differential pathlength
spectroscopy (FDPS) performed in the present study has been
described in detail previously [25]. The outline of the method
is described briefly for the readers in this manuscript. For a full
description of the technical aspects of the measurement, the filter
sets used, the quantification of system artifacts and the incorpora-
tion of spectroscopy in to the clinical workflow please refer to our
previous publication [25]. Figure 1 is a schematic representation
of the device setup. The system uses two 800µmdiameter optical
fibers located adjacent to each other and encased in a rigid probe
(the probe); one fiber is used for the delivery and collection of
light (dc) and the adjacent fiber is used for only for light collection
(c). The dc fiber is connected to a white light source, a diode laser
delivering 652 nm light and the spectrometer, while the c fiber
is connected to the spectrometer. Broad band white light and
FIGURE 1 | Setup of the FDPS system. The dc (delivery/collection) fiber in
the probe excites the tissue with white light and laser light sequentially while
both the dc and c (collection) fibers collect and transfer light to the
spectrometer.
652 nm light from a diode laser are sequentially delivered to the
tissue and enable the collection of a white light reflectance spec-
trum and the excitation and collection of mTHPC fluorescence.
Before light is led to the spectrometer, both fibers pass through a
notch filter; this filters the light from the laser source, thus pre-
venting saturation of the fluorescence spectroscopy system. This
results in a small wavelength band over which reflectance spec-
tra are associated with significant levels of noise. Each sequence
of measurements is combined with an appropriate calibration
procedure such that differential reflectance (DR) and differential
fluorescence (DF) spectra are recorded from the tissue of interest.
Data Analysis
The DR is fitted to an empirical model that incorporates the pres-
ence of a background scattering model that is appropriate for
tissue, and quantifies the influence of absorption on the collected
DR. The wavelength dependent absorption coefficient of tissue
of the oral cavity is described by components that are related
to various absorbers such as oxy- and de-oxyhemoglobin and
bilirubin. By accounting for the non-homogeneous distribution
of blood in tissue, these components are appropriately combined
to yield various physiological parameters: the blood volume frac-
tion (BVF); the microvascular oxygen saturation; the average
microvasculature blood vessel diameter and the concentration of
bilirubin. A least squares fitting procedure is performed that pro-
vides estimated mean values and confidence intervals for each of
these parameters.
The calibrated DF (expressed in units of photon
counts/ms/mW) is corrected for the effects of absorption
by multiplying the DF by the ratio of the DR at the excitation
wavelength (652 nm) with and without absorbers present. The
value of DR in the presence of absorption is calculated from the
fit of data to the empirical model described above while the DR
in the absence of absorption is estimated from the background
scattering model. This corrected DF is then analyzed as a linear
combination of basis spectra that comprise the autofluorescence
of the oral mucosa, mTHPC fluorescence, and a small signal
attributable to the background fluorescence from the optical
components of the system. Basis spectra for each of these compo-
nents were determined from the average of 5 DF measurements
in the oral cavity with and without the presence of mTHPC.
High quality fitting of mTHPC fluorescence and physio-
logical parameters were achieved in the majority of acquisi-
tions even in the presence of low blood volumes. Figure 2
shows a representative example of DR and DF spectra and their
components. Individual spectra are excluded based on the pres-
ence of observable features in the residual between the model
fit and the data as shown in Figure 2, and are not used in the
calculation of mean fluorescence.
The DF attributable to the photosensitizer (mTHPC) (this
value is expressed as “fluorescence” in the rest of the text), was
acquired in three sequential measurements by placing, removing,
and replacing the FDPS probe from three different sites of the TC,
margins of the tumor located in the illumination field as safety
margin [tumor margin (TM)], and normal non-illuminated
mucosa (NM). Measurements at each site are averaged to yield
one value and a standard deviation. The photobleaching of
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FIGURE 2 | The DPS (left) and FDPS (right) spectra from a center
of the tumor before PDT. The absorption of light by the tissue as
seen by the difference between the scattering model and the measured
reflectance (DR) is used to calculate oxygen saturation, blood volume
fraction, and vessel diameter and to correct the measured fluorescence
for absorption. The noise at around 652 nm is due to the notch filter.
The components of the measured fluorescence (DF) are
autofluorescence of the tissue (autoFL), fluorescence of the FDPS
system used (system FL) and fluorescence attributable to mTHPC
(mTHPC). The effect of the filter is not visible on the FDPS spectrum,
because the spectrum is a plot of around 675 nm and longer
wavelengths. The “residual” plot underneath the spectra represents the
residual between the model fit and the collected data. Residuals
between 0.2 and -0.2 are assumed as acceptable.
mTHPC was quantified by the percentage decrease in mTHPC
fluorescence calculated using the average values immediately
before and after illumination for each site separately. If the
BVF in any single DR measurement was high (>50%) flu-
orescence measurements were repeated after removing excess
blood from the measurement area and the probe tip. The
reflectance measurements were considered feasible for analysis if
the DVF was between 0.3 and 50%. The interpretation of indi-
vidual combinations of sequential co-localized reflectance and
fluorescence spectroscopy are discussed further in the Results
Section.
Patients were followed at least 1 year to detect any par-
tial response or recurrence of the tumor at the treated site.
The treatment failures (if any detected) were coupled to the
measured spectra in an effort to explain the reason(s) of the
failure.
Statistical Analysis
The significance of differences in mean fluorescence intensity
and physiological parameters were assessed using an unpaired
Student’s t-test (with an α = 0.05).
Results
Twenty-four patients with 27 oral cavity lesions were included
in the study. Seventy eight percent of the spectra obtained were
suitable for analysis using the criteria described in the methods.
Variability in mTHPC Fluorescence and Tumor
Selectivity
The fluorescence measured at the TC before PDT ranged from
3.02 to 0.09 photon counts/ms/mw with a mean of 1.33 ±
0.77. The mean fluorescence measured at TM was similar to
mean fluorescence at TC before PDT [1.27 ± 0.49 vs. 1.33 ±
0.77, respectively (p = 0.84)], whereas the mean fluorescence
measured at NM (0.95 ± 0.47) was lower but not statistically
significantly lower (p = 0.25). It is evident from high stan-
dard deviations that there is considerable variation inter-subject.
When average fluorescence of TC, TM, and NM are plotted per
patient/lesion (Figure 3), the mean TC/NM ratio of fluorescence
was 1.50 ± 0.66. It can be seen from Figure 3 that, although true
for the majority, not in all cases the TC contain more photosen-
sitizer than NM. There is no observable difference between TC
and TM with a TC/TM ratio of 1.18 ± 0.53. Two lesions (no. 12
and 13) showed very low fluorescence in all measured locations
before PDT (Figure 3) (p < 0.05).
Photobleaching of mTHPC
The hypothesized reaction is a decrease in fluorescence as a result
of PDT (Figure 4), referred to as photobleaching. The fluores-
cence after PDT at the TC ranged from 0.74 to 0.02. Taking into
account the large range of fluorescence observed, we have decided
to compare the fluorescence decrease (photobleaching) as a unit
of percentage decrease calculated for each individual case. The
mean photobleaching was 81 ± 17% with a range of 99 to 7%
at TC (Figure 5). Twenty four lesions have shown the hypothe-
sized pattern of photobleaching with decrease in fluorescence due
to PDT. In addition to two lesions with very low fluorescence,
one lesion has shown almost no photobleaching, with only 7%
decrease in fluorescence due to PDT. The mean photobleaching
of the 24 lesions with the hypothesized reaction is 85± 10% with
a range of 99 to 66%.
There was somewhat less photobleaching at the TM follow-
ing PDT (this was not statistically significant, p = 0.42. The
mean photobleaching was 61% ± 25% with a range of 91%
to -6%. The photobleaching of -6% is seen along the margins
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FIGURE 3 | Fluorescence attributable to mTHPC at tumor center, margin, and normal mucosa before PDT in all measured lesions. TC had average 1.50
times more fluorescence than NM but with a high standard deviation (0.66). It can be seen that in some cases NM has more fluorescence than TC.
FIGURE 4 | FDPS (above) and DPS (below) spectra measured before
and after PDT, demonstrating the anticipated photobleaching. The
blue line in the fluorescence spectra (above) represents the fluorescence
attributable to mTHPC. It can be observed that the fluorescence peak
between 700 and 740 nm wavelength decreases due to breakdown of
mTHPC during PDT.
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FIGURE 5 | Average mTHPC fluorescence measured in the TC
(blue bars; panel A), TM (red bars, panel B), and NM (green bars;
panel C). Panel D show the percentage of mTHPC fluorescence
photobleached before and after illumination at the TC (blue bars) and
TM red bars. Lesions number 12 and 13 show very low fluorescence
indicating low concentrations of mTHPC. Lesion number 8 shows no
photobleaching (difference before and after PDT). Lesions 1, 2, 8, 15,
and 24 show less than 50% photobleaching at tumor margins
suggesting a geographic miss. There is no evident photobleaching in
normal mucosa that did not receive PDT (panel C). Missing or data that
could not be evaluated are left blank. The numbers in all three graphs
correspond to the same lesion/patient.
of the tumor that showed negligible photobleaching at the TC
mentioned in the paragraph above (lesion 8). There are four
additional photobleaching below 50% at TM (lesions 1, 2, 15,
and 24) (Figure 5). There was no significant photobleaching of
mTHPC observed in NM that was not illuminated. The aver-
age difference before and after PDT was −5% ± 23 at NM
(Figure 5).
Differential Path-Length Spectroscopy
The weighted mean oxygen saturation was slightly lower at TC
than NM, and the vessel diameter was slightly greater in TC than
NM (Table 1). However, these values are not significant due to
the large standard deviations. There was no detectable difference
in oxygen saturation, BVF and vessel diameter before and after
PDT in any of the measurement sites.
Correlation of Spectroscopic Measurements with
Clinical Results
Out of 27 treated tumors eight had incomplete response or early
recurrence (lesions 1, 8, 12, 13, 22, 23, 25, 27). When the spec-
troscopy data was analyzed three types of possible reasons of
failure were identified for four of the lesions treated (lesions 1,
8, 12, 13).
TABLE 1 | Weighted mean (and standard deviation) blood volume fraction
(BVF), oxygen saturation (StO2), and Dv blood vessel diameter of TC and
NM before.
Site (lesion number) BVF StO2 Vessel diameter
TC (n = 27) 0.0161 (0.0130) 0.872 (0.211) 0.0171 (0.0069)
NM (n = 22) 0.0157 (0.0061) 0.966 (0.229) 0.0149 (0.0061)
(a) Insufficient photosensitizer content in the tumor: Signifi-
cantly low fluorescence was measured in two treated lesions.
Lesion number 12 had fluorescence of 0.29 and lesion num-
ber 13 had fluorescence of 0.09 compared to mean fluores-
cence of 1.33 before PDT at TC. Such low values suggest
absence of the photosensitizer in the treated lesions. Both
tumors (in two patients) had no response to PDT (Figure 5).
In Figure 6, examples of DPS and FDPS spectra of lesion 12,
before and after PDT can be seen. There was no detectable
difference in the fluorescence peaks before and after PDT.
(b) Insufficient photobleaching: Lesion number 8 showed no
change in fluorescence before and after PDT (0.64 vs. 0.60)
at TC (Figure 5). This patient had bleeding and hematoma
formation during PDT which was also detectable with some
reflectance spectra with a very high BVF. Figure 7 shows
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FIGURE 6 | FDPS (above) and DPS (below) spectra of lesion 12 before and after PDT. The blue lines in FDPS spectra are almost flat, indicating very small
concentrations of mTHPC in the TC, both before and after PDT.
FIGURE 7 | FDPS (above) and DPS (below) spectra of lesion 8, before
and after PDT, demonstrating nsufficient (absent) photobleaching. As
evident in the FDPS spectra (above), there is no decrease in fluorescence
attributable to mTHPC (blue lines), after PDT. This can be explained by the
filtering effect of excessive blood in the treated tissue. The presence of
excessive blood can be observed in the reflectance spectrum post PDT
(below). The absorbance peaks of hemoglobin between 500 and 650 nm
post PDT are much deeper compared to pre PDT.
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DPS and FDPS spectra before and after PDT. It can be
seen that the fluorescence peaks does not change as a result
of PDT. The absorption bands of hemoglobin are deep
indicating considerable blood content in the interrogated tis-
sue. Hemoglobin can absorb treatment light, acting as a filter,
preventing light to reach the tumor (Figure 7).
(c) Geographical miss/insufficient treatment to margins:
Lesion number 1, 2, 8, 15, and 24 showed less than 50%
decrease in fluorescence in the treatment margins (TM) with
PDT. Of these lesions number 8 had also insufficient pho-
tobleaching at the center of the lesion (Figure 5). The oth-
ers had good photobleaching at TC. Lesion number 1 had
good response to PDT but local recurrence within 2 months
after treatment. The other lesions had complete sustainable
response to PDT.
Collating fluorescence and blood physiology data from all lesion
sites (TC and TM) we were unable to find any correlation
between the physiological parameters (DVF and blood satura-
tion) and the extent of mTHPC photobleaching induced by the
treatment. Apart from dramatic increase in the optical proper-
ties of the illuminated volume in example b, described above, we
did not find any correlation between BVF and StO2 and lesion
response. It is important to note that four lesions (22, 23, 25,
27) showed an incomplete response for reasons that we were
unable to determine using superficial FDPS as it was applied in
the present study. Potential reasons for the lack of complete cor-
relation between optical parameters and in-complete response
are presented in our discussion.
Discussion
The results of our study showed that it was possible to incorporate
optical measurements without compromising the clinical flow of
PDT in the oral cavity. FDPS spectra were successfully acquired
in 78% of measurements. In the remaining subset of measure-
ments spectra were not able to be analyzed due to improper con-
tact between the probe and the lesion or the contralateral NM.
This kind of aberrant data are easily recognizable by inspecting
the residual between the component basis spectra and the data.
Measurements with a very low BVF (below 0.03%) were excluded
from reflectance analysis and the determination of physiological
parameters, because they introduced large errors, in particular
to the determination of the blood saturation and vessel diame-
ter. However, these reflectance measurements were retained for
the determination of absorption corrected fluorescence and were
included in our analysis of fluorescence. Measurements with an
excessively high blood volume (above 50%) were not included
in our fluorescence analysis because this BVF is only possible in
the presence of free blood. In this case reflectance measurements
were used to either inform the repetition of FDPS measurements
after the removal of free blood or to note the presence of blood
that may have shielded the therapeutic illumination volume. The
fluorescence attributable tomTHPC showed a (very) large patient
to patient variation. However, the measured values were com-
parable and consistent among the measurements performed in
the same patient/lesion. We therefore conclude that these large
variations are due to real variations in photosensitizer concen-
tration in individual patients. Measurement of consistent values
of fluorescence in unilluminated NM before and after PDT sup-
ported this observation. These variations inmTHPC fluorescence
present in the target tissue, immediately prior to the therapeutic
illumination, are in spite of the fact that the administered mTHPc
dose and drug light interval are the same for each patient. This
variability could be caused by variations in drug metabolism and
pharmacokinetics from patient to patient. Kiesslich et al have
reported variations in mTHPC uptake in a series of colangio-
carcinoma cell-lines [26] and the variations that we observe in
the present clinical study may be influenced by the cell biology
of the lesions under investigation, with some tumor cell popula-
tions taking-up and retaining more mTHPC than others. Indeed
Mitra et al. have previously reported heterogenous distribution
of mTHPC in murine cancer models [27]. We did not observe
significant spatial variations in our measurements which were
repeated at the center or margin of superficial tumors. It is prob-
able that the size of our optical probe was large enough to average
out the micro-/mesoscopic variations in mTHPC distribution.
Given the wide variation in measured mTHPC concentration it
is remarkable that we observed almost no uptake of mTHPC in
the TC, TM or in the contralateral NM in two patients. These
measurements could have been the lower range of the variation
observed in fluorescence. However, both of the lesions exhibited
none of the usual responses immediately following PDT, such
as edema, pain, or sloughing of the mucosa. These tumors were
unaffected by the therapeutic illumination. Taken in isolation it
is rather speculative to use FDPS data from the tumor and NM
to explain what is a concerning important clinical phenomenon.
Even though each patient had the Foscan injection according to
the same protocol, mTHPC failed to reach the target tissue. In
addition both of the patients had second degree burns around
the injection site and along the arm vein injected in the direc-
tion of the shoulder. This strongly suggests that there might have
been either a leak from the vessel walls, or mTHPC was injected
in the soft tissue rather than the vein. It is obviously not possi-
ble to determine the threshold lesion/NMmTHPC concentration
range at which these types of practical clinical considerations
should be considered. It is however clear that there is a need for
additional studies to determine if problems associated with the
improper injection of Foscan can be measured, preferably, prior
to the patient being admitted to hospital and undergoing PDT
treatment planning. Preliminary measurements, data not shown,
suggest that an optical measurement at the injection site and/or in
the normal oral mucosa some-time after the injection of Foscan
but before the patient is admitted could be a useful tool. At the
very least the clinical team should be planning for possible addi-
tional treatments such as surgery, radiotherapy or repeat PDT
when this is applicable. If PDT is to be repeated the photosen-
sitizer should not be injected at the previous injection site. Since
there is probably residual extravasated photosensitizer at this site
any additional injection would only increase the risk of serious
adverse events.
Neglecting patients with very low systemic concentrations of
mTHPC, on average, the TC contained 1.5 times more mTHPC
than NM. Even in our small data set it is not evident that
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malignant tissue always contains more mTHPC than NM. In
some patients NM contained more photosensitizer than the TC.
This is despite the fact that earlier animal studies have shown
higher tumor/muscle and tumor/skin concentration ratios of
mTHPC [28]. This tumor selectivity is not evident when clinical
tumors are compared to mucosa. Blant et al. reported have pre-
viously reported no difference in mTHPC concentration between
early stage SCC and NM [29]. They were able to detect slightly
higher mTHPC concentration in advanced stage SCC. Clearly it
should be kept in mind that animal models do not correlate well
with the distribution of mTHPC in humans [30, 31]. While the
lack of tumor to normal tissue selectivity is not a limiting factor
for the treatment of superficial oral lesions, where normal tissue is
protected by optical shielding, the treatment of interstitial tumors
surrounded by normal tissue [32] using Foscan is a well-known
concern.
While the average values of the vascular parameters observed
in the present study are consistent with a previous study in the
oral cavity using DPS [33, 34] the variation in our parameter
measurements is somewhat lager. It may be that the thickness
of the avascular keratin layers is different in different patient
populations. We found no specific trend of increase or decrease
observed in any of the blood related parameters before and
after PDT. It should be kept in mind that the data presented
in this manuscript are collected from superficial tumors with
excellent blood supply as opposed to tumors with larger vol-
umes with aberrant neo-vascularization and necrotic centers. The
blood supply is probably rapidly replenished after the end of
the therapeutic illumination making the vascular effects of PDT
undetectable.
As we have shown the incorporation of FDPS into the clin-
ical workflow also made it possible to detect the presence of
insufficient photobleaching. In one lesion almost no difference
in fluorescence was observed before and after PDT. In this case
there was diffuse bleeding from the lesion on the day of the illu-
mination. Pressure with gauze was applied to stop the bleeding.
When the bleeding was at manageable levels the illumination
took place with frequent cleaning of the treatment surface with
vacuum suction. However, this procedure was clearly insufficient.
Reflectance spectroscopy detected a very large DVF, even though
there appeared to be no visible blood pooling. There was proba-
bly a thin film of blood either on the surface or immediately under
the mucosa. The lack of photobleaching suggests that even such
an invisible layer of blood is capable of blocking the treatment
light. In this patient this conclusion was also confirmed by lack
of clinical response to PDT. This problem can be easily corrected
during the clinical procedure. If photobleaching is not observed
the therapeutic illumination can be repeated until the photo-
bleaching is evident. Obviously while this is a clinically relevant
problem, the lack of photobleaching due to optical shielding is a
rather extreme cause of impaired photobleaching. It is very likely
that there are important underlying photobiological reasons for a
reduced rate of photobleaching and these effects need to be inves-
tigated in the larger group of patients before definitive conclu-
sions can be drawn. An additional consideration is the potential
to use fluorescence measurements to investigate the potential for
a geographic miss at the safety margins leaving potentially leaving
untreated extensions of the tumor that are invisible to the naked
eye. It is common practice with conventional methods, such as
surgery and radiation therapy, is to treat at least 5–10mm safety
margins around the visible lesion to prevent missing these exten-
sions. Tumor recurrence is thought to be dependent on the pres-
ence or absence of malignant cells in the untreated tissue. In the
small data set we have investigated in the present study one out of
four lesions showed less photobleaching in the TM and exhibited
a recurrence within 2 months, possibly indicating that an exten-
sion of the tumor wasmissed. Using optical spectroscopy it might
be possible to investigate the margins for photobleaching and
administer repeat illuminations if insufficient photobleaching is
detected.
It was not possible for us to explain all of the PDT failures in
this cohort using FDPS. A group of lesions showed incomplete
response or recurrence even though substantial photobleach-
ing was observed both at the TC and the safety margins. It is
important to recognize that while FDPS represents an effective
technique for correcting fluorescence for the influence of differ-
ences in optical absorption (µa) it does not fully correct for the
influence of differences in scattering coefficient of tissue. Here
more robust correction algorithms and approaches to quantita-
tive spectroscopy may be more appropriate [35, 36] before a full
determination of the usefulness of optical spectroscopy for mon-
itoring PDT can be made. The present study clearly shows the
potential for the incorporation of optical spectroscopy in clinical
practice and that is fact that it can help the clinician overcome
some preventable problems that seem to occur with concerning
frequency.
Conclusions
Reflectance (DPS) and fluorescence (FDPS) spectroscopy pro-
vide an insight into the working mechanism underlying PDT, by
providing data on physiology related parameters and the mea-
surement of photosensitizer fluorescence. By incorporating FDPS
into clinic it might be possible to detect clinical problems, such as
insufficient photosensitizer concentration or lack of photobleach-
ing in the target tissues. Furthermore, FDPS can be used to inves-
tigate the treatment volume for sub-optimally treated areas. The
present study clearly shows the potential for the incorporation of
optical spectroscopy in clinical practice and that it can help the
clinician overcome the challenges during treatment planning.
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